MARKET INSIGHTS
The global phage therapy market was valued at USD 40.3 million in 2024 and is projected to grow from USD 48.1 million in 2025 to USD 133 million by 2032, exhibiting a CAGR of 19.1% during the forecast period.
Phage therapy utilizes bacteriophages—viruses that specifically target and destroy bacteria—as an alternative or complementary treatment to antibiotics. These naturally occurring biological agents are particularly effective against antibiotic-resistant bacterial strains, offering a promising solution in the era of rising antimicrobial resistance. Phage therapy finds applications across human medicine, veterinary science, agriculture, and food safety.
The market growth is primarily driven by increasing antibiotic resistance, with WHO reporting over 1.27 million annual deaths directly attributable to antimicrobial resistance globally. Furthermore, recent FDA approvals for phage-based products and growing investments in clinical trials are accelerating market adoption. Key players like NPO Microgen and Phagelux are expanding their phage libraries, while partnerships between biotech firms and research institutions are fostering innovation in this space.
MARKET DYNAMICS
MARKET DRIVERS
Rising Antibiotic Resistance Crisis Accelerates Phage Therapy Adoption
The global antibiotic resistance crisis has reached alarming proportions, with nearly 5 million deaths annually associated with antimicrobial resistance. This dire situation has become a primary driver for phage therapy adoption, as bacteriophages offer targeted solutions against multi-drug resistant bacterial strains. Unlike broad-spectrum antibiotics that contribute to resistance, phage therapies demonstrate remarkable specificity - a single phage type typically attacks only one bacterial strain. This precision has gained significant traction in clinical settings, particularly for treating resistant infections like MRSA and Pseudomonas aeruginosa where antibiotic options are severely limited.
Regulatory Approvals and Clinical Trial Successes Fuel Market Confidence
Recent regulatory milestones have significantly boosted investor confidence in phage therapeutics. The successful EU approval of phage-based products for food safety applications and multiple FDA-authorized clinical trials for human therapies demonstrate growing institutional acceptance. Currently, over 30 clinical trials are investigating phage therapies worldwide, with several Phase II studies showing success rates above 70% for difficult-to-treat infections. This regulatory momentum, coupled with the FDA's 2023 updated guidance on phage therapy development, has encouraged more pharmaceutical companies to invest in bacteriophage research and commercialization.
Technological Advancements in Phage Engineering Expand Clinical Potential
Breakthroughs in synthetic biology and CRISPR-based phage engineering are overcoming historical limitations of natural phage therapies. Modern techniques now enable scientists to modify phage genomes to enhance their bactericidal effects, expand host ranges, and delay resistance development. Such engineered phages demonstrate effectiveness rates up to 90% against certain resistant pathogens in laboratory studies. These technological improvements are particularly impactful in chronic infection treatments, where customized phage cocktails show promise for conditions like cystic fibrosis-related infections.
➤ For instance, recent studies indicate phage-antibiotic combination therapies can achieve synergistic effects, with some combinations showing 100-fold greater efficacy than either treatment alone.
MARKET RESTRAINTS
Complex Regulatory Frameworks Slow Commercialization Timelines
The pharmaceutical regulatory environment struggles to accommodate phage therapy's unique characteristics, creating significant bottlenecks. Current drug approval systems are designed for uniform chemical compounds rather than living, evolving biological entities like phages. This mismatch leads to prolonged approval processes, with average clinical trial timelines exceeding 7 years for phage products - nearly twice as long as conventional antibiotics. The lack of standardized evaluation criteria across different regions further complicates global development strategies.
Manufacturing and Quality Control Challenges Limit Scale-Up
Phage production faces unique technical hurdles that constrain large-scale manufacturing. Unlike chemical drugs, phages are living organisms requiring complex cultivation processes with bacterial hosts. Maintaining batch-to-batch consistency proves particularly difficult, with purity standards often falling below 90% for certain preparations. The need for specialized containment facilities and the risk of bacterial toxin contamination further elevate production costs, putting treatment prices beyond reach for many healthcare systems.
Limited Physician Awareness Hinders Clinical Adoption
Despite growing research, physician education about phage therapy remains inadequate, creating significant adoption barriers. A recent survey revealed that less than 25% of infectious disease specialists feel confident prescribing phage treatments. This knowledge gap stems from minimal coverage in medical curricula and limited continuing education programs. The situation is compounded by the absence of standardized treatment protocols, leaving physicians uncertain about dosing regimens and potential adverse effects.
MARKET OPPORTUNITIES
Veterinary and Agricultural Applications Offer Near-Term Growth Potential
The animal health sector presents a lower regulatory barrier entry point for phage technologies, creating immediate commercial opportunities. The global animal phage therapy market already accounts for 55% of total industry revenue, driven by demand in livestock production and aquaculture. Phage-based products for poultry and swine demonstrate particularly strong adoption, reducing antibiotic use by 60-80% in some operations while maintaining equivalent efficacy against pathogens like Salmonella and E. coli.
Personalized Medicine Integration Creates High-Value Niche Markets
Advancements in rapid bacterial identification and phage matching enable truly personalized infection treatments - a capability conventional antibiotics cannot match. Several hospitals have implemented small-scale phage banks that achieve successful patient matches within 72 hours for resistant infections. This precision approach commands premium pricing, with personalized phage preparations currently ranging from $10,000 to $50,000 per treatment course. As diagnostic technologies improve, this market segment is projected to grow at 28% annually through 2030.
Strategic Partnerships Accelerate Commercial Pipeline Development
Increasing collaboration between biotech firms and pharmaceutical giants is accelerating phage therapy commercialization. Major deals in the past two years have exceeded $1 billion in combined value, with established players leveraging startups' technical expertise while providing clinical development resources. These partnerships are particularly focused on developing standardized phage products that can undergo conventional regulatory approval pathways, addressing one of the industry's most significant challenges.
MARKET CHALLENGES
Intellectual Property Uncertainties Deter Investment
The natural origin of many therapeutic phages creates complex IP landscapes that discourage investment. Current patent systems struggle to protect naturally occurring biological entities, with only about 15% of phage-related patent applications receiving full protection. This limitation makes it difficult for companies to secure exclusive rights to their discoveries, reducing incentives for large-scale R&D investment. The situation is particularly challenging for phage cocktails containing multiple naturally derived viruses.
Bacterial Resistance to Phages Threatens Long-Term Efficacy
While phages currently overcome antibiotic resistance, bacteria can and do develop phage resistance through multiple mechanisms. Laboratory studies show certain pathogens evolving resistance to single-phage treatments within days. Though cocktail approaches and phage engineering mitigate this risk, the long-term durability of phage therapies remains uncertain. This evolutionary arms race requires continuous phage library updates, adding substantial costs to treatment programs.
Reimbursement Models Lag Behind Treatment Innovation
Healthcare payment systems worldwide have not adapted to phage therapy's unique characteristics, creating financial barriers to adoption. Most insurers still classify phage treatments as experimental, leaving patients to bear full costs. In hospitals, pharmacy budgets rarely account for personalized biologics, making administrators hesitant to stock phage formulations. Without coding updates and reimbursement pathway development, even clinically successful therapies may struggle to gain widespread use.
Segment Analysis:
By Type
DsDNA Bacteriophage Segment Dominates Due to Higher Stability and Broad-Spectrum Activity
The market is segmented based on type into:
-
DsDNA Bacteriophage
-
SsDNA Bacteriophage
-
SsRNA Bacteriophage
-
Others
By Application
Animal Health Segment Leads Due to Growing Demand for Antibiotic Alternatives in Veterinary Medicine
The market is segmented based on application into:
-
Animal Health
-
Aquaculture
-
Agriculture
-
Food Industry
-
Human Health
By End User
Pharmaceutical Companies Drive Growth Through Increased R&D Investments
The market is segmented based on end user into:
-
Pharmaceutical & Biotechnology Companies
-
Academic & Research Institutions
-
Hospitals & Diagnostic Centers
-
Veterinary Clinics
COMPETITIVE LANDSCAPE
Key Industry Players
Phage Therapy Firms Accelerate R&D to Combat Antimicrobial Resistance
The global phage therapy market exhibits a dynamic competitive landscape, characterized by emerging biotech firms alongside established pharmaceutical companies. NPO Microgen leads the market with approximately 10% revenue share in 2024, leveraging its extensive phage library and established presence in Eastern European markets. The company's strategic focus on clinical applications for drug-resistant infections positions it as a market frontrunner.
Proteon Pharmaceuticals and Phagelux collectively account for 15% of market share, demonstrating strong growth through innovative applications in animal health and food safety sectors. Proteon's recent FDA-cleared bacteriophage product for poultry farming exemplifies the industry's shift toward preventive healthcare solutions. Meanwhile, Phagelux's expansion into Asian markets reflects the growing demand for antibiotic alternatives in aquaculture.
North American players are gaining momentum through strategic collaborations. Intralytix recently partnered with a major healthcare provider to develop phage-based wound care solutions, capitalizing on the $5.2 billion chronic wound management market. Similarly, Armata Pharmaceuticals completed Phase 2 trials for its Staphylococcus aureus phage therapy, signaling potential breakthroughs in human applications.
European innovators continue to advance therapeutic applications. Pherecydes Pharma secured €28 million in Series B funding for diabetic foot ulcer treatments, while Eliava BioPreparations maintains its legacy position through hospital partnerships in post-Soviet states. These developments underscore regional specialization within the broader competitive landscape.
List of Key Phage Therapy Companies Profiled
PHAGE THERAPY MARKET TRENDS
Rising Antibiotic Resistance Drives Phage Therapy Adoption
The growing prevalence of antibiotic-resistant bacterial infections has emerged as a critical driver for the phage therapy market. With over 1.27 million deaths attributed to antimicrobial resistance in 2019 alone, healthcare systems worldwide are actively exploring alternatives to conventional antibiotics. Phage therapy, with its ability to target specific bacterial strains without disrupting the microbiome, presents a promising solution. Recent clinical trials have demonstrated success rates exceeding 80% in treating resistant infections where antibiotics failed, accelerating regulatory approvals in several countries. The FDA's designation of phage therapy as a Breakthrough Therapy for certain conditions further validates its potential in addressing this global health crisis.
Other Trends
Technological Advancements in Phage Isolation
Innovations in phage identification and purification technologies are revolutionizing treatment efficacy. High-throughput sequencing platforms now enable rapid characterization of phage libraries, reducing development timelines from months to weeks. This technological leap is particularly impactful given the 90%+ market share of DsDNA bacteriophages, which require precise targeting mechanisms. Automated phage screening systems paired with AI-driven matching algorithms are achieving identification accuracy rates above 95%, making personalized phage cocktails more accessible for clinical use. These advancements are particularly crucial for human health applications, which currently represent 28% of the market but show the fastest growth trajectory.
Expansion into New Therapeutic Areas
While traditional applications in animal health dominate 55% of current market revenue, phage therapy is expanding into novel areas with significant potential. The food industry is increasingly adopting phage-based solutions for bacterial contamination control, with the global food safety testing market projected to incorporate 30% more phage-based products by 2026. Similarly, agricultural applications are growing at 22% CAGR as farmers seek alternatives to chemical biocides. Perhaps most notably, phage formulations are being developed for chronic conditions like diabetic foot ulcers and cystic fibrosis infections, opening billion-dollar treatment markets previously reliant on diminishingly effective antibiotics.
Regional Analysis: Phage Therapy Market
North America
North America dominates the global phage therapy market, accounting for the largest revenue share due to strong regulatory support, high investment in biotechnology, and growing antibiotic resistance concerns. The U.S. Food and Drug Administration (FDA) has approved several phage therapy clinical trials, with companies like Intralytix and Adaptive Phage Therapeutics leading R&D efforts. In 2023, the U.S. government allocated $290 million to combat antimicrobial resistance, indirectly fueling phage therapy innovation. The region's advanced healthcare infrastructure and willingness to adopt alternative therapies accelerate market growth. However, stringent approval processes and high treatment costs pose challenges for widespread clinical adoption.
Europe
Europe is a pioneering region in phage therapy, with Georgia’s Eliava Institute providing treatments for decades. The European Medicines Agency (EMA) has shown increasing openness to phage-based solutions, particularly for multidrug-resistant infections. Countries like Belgium and France have established regulatory frameworks for "personalized phage therapy," driving hospital-level adoption. The EU’s Horizon Europe program has funded multiple phage research initiatives, recognizing their potential in combating antimicrobial resistance. However, fragmented regulations across member states and limited commercial-scale production capabilities restrain the market’s full potential despite strong scientific expertise.
Asia-Pacific
The Asia-Pacific phage therapy market is expanding rapidly, led by China’s aggressive biotechnology investments and India’s high burden of antibiotic-resistant infections. China’s Qingdao Phagepharm Bio-tech has emerged as a key regional player, focusing on agricultural and aquaculture applications. Japan and South Korea are advancing in human clinical trials, supported by government-academia partnerships. While the region benefits from lower production costs and large patient populations, inconsistent regulatory standards and lack of awareness among healthcare providers hinder clinical adoption. Nevertheless, the market shows immense growth potential with increasing healthcare expenditure and rising antimicrobial resistance rates.
South America
South America represents a nascent but promising market, with Brazil leading in clinical research through institutions like the Oswaldo Cruz Foundation. The region’s high prevalence of bacterial infections in livestock and aquaculture has spurred experimental use of phage therapies. Argentina has shown notable progress with veterinary applications. However, political instability, inadequate funding for biotech research, and limited manufacturing infrastructure significantly slow market development. Collaborative efforts with North American and European partners are helping bridge these gaps, particularly in academic research settings.
Middle East & Africa
The Middle East & Africa region demonstrates emerging interest in phage therapy, particularly in Gulf countries with advanced medical facilities like the UAE and Saudi Arabia. South African research institutions are exploring phage applications for TB and HIV-related infections. While the region faces critical antimicrobial resistance challenges, market growth is constrained by limited local expertise, scarce funding for biotechnology, and healthcare systems prioritizing conventional treatments. International partnerships and technology transfers from developed markets are essential to unlock the region’s long-term potential in phage therapeutics.
Report Scope
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Key Coverage Areas:
FREQUENTLY ASKED QUESTIONS:
What is the current market size of Global Phage Therapy Market?
-> The global phage therapy market was valued at USD 40.3 million in 2024 and is projected to reach USD 133 million by 2032, growing at a CAGR of 19.1% during the forecast period.
Which key companies operate in Global Phage Therapy Market?
-> Key players include NPO Microgen, Proteon Pharmaceuticals, Phagelux, Intralytix, Micreos, and Eliava BioPreparations, among others. The top 3 players hold approximately 25% of the global market share.
What are the key growth drivers?
-> Key growth drivers include rising antibiotic resistance, increasing applications in animal health and agriculture, and government support for alternative antimicrobial solutions.
Which region dominates the market?
-> North America and Europe collectively account for about 60% of the global market share, with Asia-Pacific emerging as the fastest-growing region.
What are the emerging trends?
-> Emerging trends include personalized phage therapies, combination therapies with antibiotics, and expanding applications in food safety and human medicine.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Phage Therapy Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Phage Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Phage Therapy Overall Market Size
2.1 Global Phage Therapy Market Size: 2024 VS 2032
2.2 Global Phage Therapy Market Size, Prospects & Forecasts: 2020-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Phage Therapy Players in Global Market
3.2 Top Global Phage Therapy Companies Ranked by Revenue
3.3 Global Phage Therapy Revenue by Companies
3.4 Top 3 and Top 5 Phage Therapy Companies in Global Market, by Revenue in 2024
3.5 Global Companies Phage Therapy Product Type
3.6 Tier 1, Tier 2, and Tier 3 Phage Therapy Players in Global Market
3.6.1 List of Global Tier 1 Phage Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Phage Therapy Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Phage Therapy Market Size Markets, 2024 & 2032
4.1.2 DsDNA Bacteriophage
4.1.3 SsDNA Bacteriophage
4.1.4 SsRNA Bacteriophage
4.1.5 Others
4.2 Segmentation by Type - Global Phage Therapy Revenue & Forecasts
4.2.1 Segmentation by Type - Global Phage Therapy Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Phage Therapy Revenue, 2026-2032
4.2.3 Segmentation by Type - Global Phage Therapy Revenue Market Share, 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Phage Therapy Market Size, 2024 & 2032
5.1.2 Animal Health
5.1.3 Aquaculture
5.1.4 Agriculture
5.1.5 Food Industry
5.1.6 Human Health
5.1.7 Others
5.2 Segmentation by Application - Global Phage Therapy Revenue & Forecasts
5.2.1 Segmentation by Application - Global Phage Therapy Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Phage Therapy Revenue, 2026-2032
5.2.3 Segmentation by Application - Global Phage Therapy Revenue Market Share, 2020-2032
6 Sights by Region
6.1 By Region - Global Phage Therapy Market Size, 2024 & 2032
6.2 By Region - Global Phage Therapy Revenue & Forecasts
6.2.1 By Region - Global Phage Therapy Revenue, 2020-2025
6.2.2 By Region - Global Phage Therapy Revenue, 2026-2032
6.2.3 By Region - Global Phage Therapy Revenue Market Share, 2020-2032
6.3 North America
6.3.1 By Country - North America Phage Therapy Revenue, 2020-2032
6.3.2 United States Phage Therapy Market Size, 2020-2032
6.3.3 Canada Phage Therapy Market Size, 2020-2032
6.3.4 Mexico Phage Therapy Market Size, 2020-2032
6.4 Europe
6.4.1 By Country - Europe Phage Therapy Revenue, 2020-2032
6.4.2 Germany Phage Therapy Market Size, 2020-2032
6.4.3 France Phage Therapy Market Size, 2020-2032
6.4.4 U.K. Phage Therapy Market Size, 2020-2032
6.4.5 Italy Phage Therapy Market Size, 2020-2032
6.4.6 Russia Phage Therapy Market Size, 2020-2032
6.4.7 Nordic Countries Phage Therapy Market Size, 2020-2032
6.4.8 Benelux Phage Therapy Market Size, 2020-2032
6.5 Asia
6.5.1 By Region - Asia Phage Therapy Revenue, 2020-2032
6.5.2 China Phage Therapy Market Size, 2020-2032
6.5.3 Japan Phage Therapy Market Size, 2020-2032
6.5.4 South Korea Phage Therapy Market Size, 2020-2032
6.5.5 Southeast Asia Phage Therapy Market Size, 2020-2032
6.5.6 India Phage Therapy Market Size, 2020-2032
6.6 South America
6.6.1 By Country - South America Phage Therapy Revenue, 2020-2032
6.6.2 Brazil Phage Therapy Market Size, 2020-2032
6.6.3 Argentina Phage Therapy Market Size, 2020-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Phage Therapy Revenue, 2020-2032
6.7.2 Turkey Phage Therapy Market Size, 2020-2032
6.7.3 Israel Phage Therapy Market Size, 2020-2032
6.7.4 Saudi Arabia Phage Therapy Market Size, 2020-2032
6.7.5 UAE Phage Therapy Market Size, 2020-2032
7 Companies Profiles
7.1 NPO Microgen
7.1.1 NPO Microgen Corporate Summary
7.1.2 NPO Microgen Business Overview
7.1.3 NPO Microgen Phage Therapy Major Product Offerings
7.1.4 NPO Microgen Phage Therapy Revenue in Global Market (2020-2025)
7.1.5 NPO Microgen Key News & Latest Developments
7.2 Proteon Pharmaceuticals
7.2.1 Proteon Pharmaceuticals Corporate Summary
7.2.2 Proteon Pharmaceuticals Business Overview
7.2.3 Proteon Pharmaceuticals Phage Therapy Major Product Offerings
7.2.4 Proteon Pharmaceuticals Phage Therapy Revenue in Global Market (2020-2025)
7.2.5 Proteon Pharmaceuticals Key News & Latest Developments
7.3 Phagelux
7.3.1 Phagelux Corporate Summary
7.3.2 Phagelux Business Overview
7.3.3 Phagelux Phage Therapy Major Product Offerings
7.3.4 Phagelux Phage Therapy Revenue in Global Market (2020-2025)
7.3.5 Phagelux Key News & Latest Developments
7.4 Intralytix
7.4.1 Intralytix Corporate Summary
7.4.2 Intralytix Business Overview
7.4.3 Intralytix Phage Therapy Major Product Offerings
7.4.4 Intralytix Phage Therapy Revenue in Global Market (2020-2025)
7.4.5 Intralytix Key News & Latest Developments
7.5 Micreos
7.5.1 Micreos Corporate Summary
7.5.2 Micreos Business Overview
7.5.3 Micreos Phage Therapy Major Product Offerings
7.5.4 Micreos Phage Therapy Revenue in Global Market (2020-2025)
7.5.5 Micreos Key News & Latest Developments
7.6 Eliava BioPreparations
7.6.1 Eliava BioPreparations Corporate Summary
7.6.2 Eliava BioPreparations Business Overview
7.6.3 Eliava BioPreparations Phage Therapy Major Product Offerings
7.6.4 Eliava BioPreparations Phage Therapy Revenue in Global Market (2020-2025)
7.6.5 Eliava BioPreparations Key News & Latest Developments
7.7 Locus Biosciences,Inc
7.7.1 Locus Biosciences,Inc Corporate Summary
7.7.2 Locus Biosciences,Inc Business Overview
7.7.3 Locus Biosciences,Inc Phage Therapy Major Product Offerings
7.7.4 Locus Biosciences,Inc Phage Therapy Revenue in Global Market (2020-2025)
7.7.5 Locus Biosciences,Inc Key News & Latest Developments
7.8 Pharmex Group,LLC
7.8.1 Pharmex Group,LLC Corporate Summary
7.8.2 Pharmex Group,LLC Business Overview
7.8.3 Pharmex Group,LLC Phage Therapy Major Product Offerings
7.8.4 Pharmex Group,LLC Phage Therapy Revenue in Global Market (2020-2025)
7.8.5 Pharmex Group,LLC Key News & Latest Developments
7.9 Pherecydes Pharma
7.9.1 Pherecydes Pharma Corporate Summary
7.9.2 Pherecydes Pharma Business Overview
7.9.3 Pherecydes Pharma Phage Therapy Major Product Offerings
7.9.4 Pherecydes Pharma Phage Therapy Revenue in Global Market (2020-2025)
7.9.5 Pherecydes Pharma Key News & Latest Developments
7.10 APS Biocontrol Ltd. (APS)
7.10.1 APS Biocontrol Ltd. (APS) Corporate Summary
7.10.2 APS Biocontrol Ltd. (APS) Business Overview
7.10.3 APS Biocontrol Ltd. (APS) Phage Therapy Major Product Offerings
7.10.4 APS Biocontrol Ltd. (APS) Phage Therapy Revenue in Global Market (2020-2025)
7.10.5 APS Biocontrol Ltd. (APS) Key News & Latest Developments
7.11 Qingdao Phagepharm Bio-tech
7.11.1 Qingdao Phagepharm Bio-tech Corporate Summary
7.11.2 Qingdao Phagepharm Bio-tech Business Overview
7.11.3 Qingdao Phagepharm Bio-tech Phage Therapy Major Product Offerings
7.11.4 Qingdao Phagepharm Bio-tech Phage Therapy Revenue in Global Market (2020-2025)
7.11.5 Qingdao Phagepharm Bio-tech Key News & Latest Developments
7.12 Fixed-Phage Limited
7.12.1 Fixed-Phage Limited Corporate Summary
7.12.2 Fixed-Phage Limited Business Overview
7.12.3 Fixed-Phage Limited Phage Therapy Major Product Offerings
7.12.4 Fixed-Phage Limited Phage Therapy Revenue in Global Market (2020-2025)
7.12.5 Fixed-Phage Limited Key News & Latest Developments
7.13 Zeptometrix
7.13.1 Zeptometrix Corporate Summary
7.13.2 Zeptometrix Business Overview
7.13.3 Zeptometrix Phage Therapy Major Product Offerings
7.13.4 Zeptometrix Phage Therapy Revenue in Global Market (2020-2025)
7.13.5 Zeptometrix Key News & Latest Developments
7.14 Phage International, Inc.
7.14.1 Phage International, Inc. Corporate Summary
7.14.2 Phage International, Inc. Business Overview
7.14.3 Phage International, Inc. Phage Therapy Major Product Offerings
7.14.4 Phage International, Inc. Phage Therapy Revenue in Global Market (2020-2025)
7.14.5 Phage International, Inc. Key News & Latest Developments
7.15 MicroMir
7.15.1 MicroMir Corporate Summary
7.15.2 MicroMir Business Overview
7.15.3 MicroMir Phage Therapy Major Product Offerings
7.15.4 MicroMir Phage Therapy Revenue in Global Market (2020-2025)
7.15.5 MicroMir Key News & Latest Developments
7.16 iNtODEWORLD, Inc.
7.16.1 iNtODEWORLD, Inc. Corporate Summary
7.16.2 iNtODEWORLD, Inc. Business Overview
7.16.3 iNtODEWORLD, Inc. Phage Therapy Major Product Offerings
7.16.4 iNtODEWORLD, Inc. Phage Therapy Revenue in Global Market (2020-2025)
7.16.5 iNtODEWORLD, Inc. Key News & Latest Developments
7.17 NEXTBIOTICS
7.17.1 NEXTBIOTICS Corporate Summary
7.17.2 NEXTBIOTICS Business Overview
7.17.3 NEXTBIOTICS Phage Therapy Major Product Offerings
7.17.4 NEXTBIOTICS Phage Therapy Revenue in Global Market (2020-2025)
7.17.5 NEXTBIOTICS Key News & Latest Developments
7.18 Armata Pharmaceuticals, Inc.
7.18.1 Armata Pharmaceuticals, Inc. Corporate Summary
7.18.2 Armata Pharmaceuticals, Inc. Business Overview
7.18.3 Armata Pharmaceuticals, Inc. Phage Therapy Major Product Offerings
7.18.4 Armata Pharmaceuticals, Inc. Phage Therapy Revenue in Global Market (2020-2025)
7.18.5 Armata Pharmaceuticals, Inc. Key News & Latest Developments
7.19 Innophage
7.19.1 Innophage Corporate Summary
7.19.2 Innophage Business Overview
7.19.3 Innophage Phage Therapy Major Product Offerings
7.19.4 Innophage Phage Therapy Revenue in Global Market (2020-2025)
7.19.5 Innophage Key News & Latest Developments
7.20 Adaptive Phage Therapeutics
7.20.1 Adaptive Phage Therapeutics Corporate Summary
7.20.2 Adaptive Phage Therapeutics Business Overview
7.20.3 Adaptive Phage Therapeutics Phage Therapy Major Product Offerings
7.20.4 Adaptive Phage Therapeutics Phage Therapy Revenue in Global Market (2020-2025)
7.20.5 Adaptive Phage Therapeutics Key News & Latest Developments
7.21 TechnoPhage
7.21.1 TechnoPhage Corporate Summary
7.21.2 TechnoPhage Business Overview
7.21.3 TechnoPhage Phage Therapy Major Product Offerings
7.21.4 TechnoPhage Phage Therapy Revenue in Global Market (2020-2025)
7.21.5 TechnoPhage Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Phage Therapy Market Opportunities & Trends in Global Market
Table 2. Phage Therapy Market Drivers in Global Market
Table 3. Phage Therapy Market Restraints in Global Market
Table 4. Key Players of Phage Therapy in Global Market
Table 5. Top Phage Therapy Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Phage Therapy Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Phage Therapy Revenue Share by Companies, 2020-2025
Table 8. Global Companies Phage Therapy Product Type
Table 9. List of Global Tier 1 Phage Therapy Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Phage Therapy Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type � Global Phage Therapy Revenue, (US$, Mn), 2024 & 2032
Table 12. Segmentation by Type - Global Phage Therapy Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Phage Therapy Revenue (US$, Mn), 2026-2032
Table 14. Segmentation by Application� Global Phage Therapy Revenue, (US$, Mn), 2024 & 2032
Table 15. Segmentation by Application - Global Phage Therapy Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Phage Therapy Revenue, (US$, Mn), 2026-2032
Table 17. By Region� Global Phage Therapy Revenue, (US$, Mn), 2024 & 2032
Table 18. By Region - Global Phage Therapy Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Phage Therapy Revenue, (US$, Mn), 2026-2032
Table 20. By Country - North America Phage Therapy Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Phage Therapy Revenue, (US$, Mn), 2026-2032
Table 22. By Country - Europe Phage Therapy Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Phage Therapy Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Asia Phage Therapy Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Phage Therapy Revenue, (US$, Mn), 2026-2032
Table 26. By Country - South America Phage Therapy Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Phage Therapy Revenue, (US$, Mn), 2026-2032
Table 28. By Country - Middle East & Africa Phage Therapy Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Phage Therapy Revenue, (US$, Mn), 2026-2032
Table 30. NPO Microgen Corporate Summary
Table 31. NPO Microgen Phage Therapy Product Offerings
Table 32. NPO Microgen Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 33. NPO Microgen Key News & Latest Developments
Table 34. Proteon Pharmaceuticals Corporate Summary
Table 35. Proteon Pharmaceuticals Phage Therapy Product Offerings
Table 36. Proteon Pharmaceuticals Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 37. Proteon Pharmaceuticals Key News & Latest Developments
Table 38. Phagelux Corporate Summary
Table 39. Phagelux Phage Therapy Product Offerings
Table 40. Phagelux Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 41. Phagelux Key News & Latest Developments
Table 42. Intralytix Corporate Summary
Table 43. Intralytix Phage Therapy Product Offerings
Table 44. Intralytix Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 45. Intralytix Key News & Latest Developments
Table 46. Micreos Corporate Summary
Table 47. Micreos Phage Therapy Product Offerings
Table 48. Micreos Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 49. Micreos Key News & Latest Developments
Table 50. Eliava BioPreparations Corporate Summary
Table 51. Eliava BioPreparations Phage Therapy Product Offerings
Table 52. Eliava BioPreparations Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 53. Eliava BioPreparations Key News & Latest Developments
Table 54. Locus Biosciences,Inc Corporate Summary
Table 55. Locus Biosciences,Inc Phage Therapy Product Offerings
Table 56. Locus Biosciences,Inc Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 57. Locus Biosciences,Inc Key News & Latest Developments
Table 58. Pharmex Group,LLC Corporate Summary
Table 59. Pharmex Group,LLC Phage Therapy Product Offerings
Table 60. Pharmex Group,LLC Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 61. Pharmex Group,LLC Key News & Latest Developments
Table 62. Pherecydes Pharma Corporate Summary
Table 63. Pherecydes Pharma Phage Therapy Product Offerings
Table 64. Pherecydes Pharma Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 65. Pherecydes Pharma Key News & Latest Developments
Table 66. APS Biocontrol Ltd. (APS) Corporate Summary
Table 67. APS Biocontrol Ltd. (APS) Phage Therapy Product Offerings
Table 68. APS Biocontrol Ltd. (APS) Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 69. APS Biocontrol Ltd. (APS) Key News & Latest Developments
Table 70. Qingdao Phagepharm Bio-tech Corporate Summary
Table 71. Qingdao Phagepharm Bio-tech Phage Therapy Product Offerings
Table 72. Qingdao Phagepharm Bio-tech Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 73. Qingdao Phagepharm Bio-tech Key News & Latest Developments
Table 74. Fixed-Phage Limited Corporate Summary
Table 75. Fixed-Phage Limited Phage Therapy Product Offerings
Table 76. Fixed-Phage Limited Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 77. Fixed-Phage Limited Key News & Latest Developments
Table 78. Zeptometrix Corporate Summary
Table 79. Zeptometrix Phage Therapy Product Offerings
Table 80. Zeptometrix Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 81. Zeptometrix Key News & Latest Developments
Table 82. Phage International, Inc. Corporate Summary
Table 83. Phage International, Inc. Phage Therapy Product Offerings
Table 84. Phage International, Inc. Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 85. Phage International, Inc. Key News & Latest Developments
Table 86. MicroMir Corporate Summary
Table 87. MicroMir Phage Therapy Product Offerings
Table 88. MicroMir Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 89. MicroMir Key News & Latest Developments
Table 90. iNtODEWORLD, Inc. Corporate Summary
Table 91. iNtODEWORLD, Inc. Phage Therapy Product Offerings
Table 92. iNtODEWORLD, Inc. Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 93. iNtODEWORLD, Inc. Key News & Latest Developments
Table 94. NEXTBIOTICS Corporate Summary
Table 95. NEXTBIOTICS Phage Therapy Product Offerings
Table 96. NEXTBIOTICS Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 97. NEXTBIOTICS Key News & Latest Developments
Table 98. Armata Pharmaceuticals, Inc. Corporate Summary
Table 99. Armata Pharmaceuticals, Inc. Phage Therapy Product Offerings
Table 100. Armata Pharmaceuticals, Inc. Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 101. Armata Pharmaceuticals, Inc. Key News & Latest Developments
Table 102. Innophage Corporate Summary
Table 103. Innophage Phage Therapy Product Offerings
Table 104. Innophage Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 105. Innophage Key News & Latest Developments
Table 106. Adaptive Phage Therapeutics Corporate Summary
Table 107. Adaptive Phage Therapeutics Phage Therapy Product Offerings
Table 108. Adaptive Phage Therapeutics Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 109. Adaptive Phage Therapeutics Key News & Latest Developments
Table 110. TechnoPhage Corporate Summary
Table 111. TechnoPhage Phage Therapy Product Offerings
Table 112. TechnoPhage Phage Therapy Revenue (US$, Mn) & (2020-2025)
Table 113. TechnoPhage Key News & Latest Developments
List of Figures
Figure 1. Phage Therapy Product Picture
Figure 2. Phage Therapy Segment by Type in 2024
Figure 3. Phage Therapy Segment by Application in 2024
Figure 4. Global Phage Therapy Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Phage Therapy Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Phage Therapy Revenue: 2020-2032 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Phage Therapy Revenue in 2024
Figure 9. Segmentation by Type � Global Phage Therapy Revenue, (US$, Mn), 2024 & 2032
Figure 10. Segmentation by Type - Global Phage Therapy Revenue Market Share, 2020-2032
Figure 11. Segmentation by Application � Global Phage Therapy Revenue, (US$, Mn), 2024 & 2032
Figure 12. Segmentation by Application - Global Phage Therapy Revenue Market Share, 2020-2032
Figure 13. By Region - Global Phage Therapy Revenue Market Share, 2020-2032
Figure 14. By Country - North America Phage Therapy Revenue Market Share, 2020-2032
Figure 15. United States Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 16. Canada Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 17. Mexico Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 18. By Country - Europe Phage Therapy Revenue Market Share, 2020-2032
Figure 19. Germany Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 20. France Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 21. U.K. Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 22. Italy Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 23. Russia Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 24. Nordic Countries Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 25. Benelux Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 26. By Region - Asia Phage Therapy Revenue Market Share, 2020-2032
Figure 27. China Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 28. Japan Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 29. South Korea Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 30. Southeast Asia Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 31. India Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 32. By Country - South America Phage Therapy Revenue Market Share, 2020-2032
Figure 33. Brazil Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 34. Argentina Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 35. By Country - Middle East & Africa Phage Therapy Revenue Market Share, 2020-2032
Figure 36. Turkey Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 37. Israel Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 38. Saudi Arabia Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 39. UAE Phage Therapy Revenue, (US$, Mn), 2020-2032
Figure 40. NPO Microgen Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. Proteon Pharmaceuticals Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. Phagelux Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. Intralytix Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. Micreos Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. Eliava BioPreparations Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. Locus Biosciences,Inc Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. Pharmex Group,LLC Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. Pherecydes Pharma Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 49. APS Biocontrol Ltd. (APS) Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 50. Qingdao Phagepharm Bio-tech Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 51. Fixed-Phage Limited Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 52. Zeptometrix Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 53. Phage International, Inc. Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 54. MicroMir Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 55. iNtODEWORLD, Inc. Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 56. NEXTBIOTICS Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 57. Armata Pharmaceuticals, Inc. Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 58. Innophage Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 59. Adaptive Phage Therapeutics Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 60. TechnoPhage Phage Therapy Revenue Year Over Year Growth (US$, Mn) & (2020-2025)